Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PETX

Aratana Therapeutics (PETX) Stock Price, News & Analysis

Aratana Therapeutics logo

About Aratana Therapeutics Stock (NASDAQ:PETX)

Advanced Chart

Key Stats

Today's Range
$4.92
$4.92
50-Day Range
$4.92
$4.92
52-Week Range
$3.30
$7.16
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$241.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PETX Stock News Headlines

PETX_old Historical Data
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
5 Stocks Under $10 to Trade for Big Breakouts
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
See More Headlines

PETX Stock Analysis - Frequently Asked Questions

Aratana Therapeutics Inc (NASDAQ:PETX) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative trailing twelve-month return on equity of 12.99% and a negative net margin of 33.47%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
11/01/2018
Today
8/26/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PETX
CIK
1509190
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.72 million
Net Margins
-33.47%
Pretax Margin
N/A
Return on Equity
-12.99%
Return on Assets
-10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.66
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$35.41 million
Price / Sales
6.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
49,000,000
Free Float
N/A
Market Cap
$241.08 million
Optionable
Optionable
Beta
1.40
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PETX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners